Atrial Fibrillation

Atrial fibrillation (AFib) is the most common sustained heart rhythm disorder affecting 10M people in the U.S. (33M worldwide) with the prevalence increasing 3-fold in the past 50 years.

• AF causes significant morbidity and mortality

  • People suffering with AFib have ~6x higher risk of stroke

  • Risk of Heart Attack (MI) increases ~ 2x

  • Leading cause of Congestive Heart Failure (~50%)

  • Direct medical costs associated with AFib total $23 billion per year in the US.

• The incidence increases with age, making AF an ‘epidemic’ in an aging population.

  • Lifetime risk of AFib is 1 in 3 for people over 50

  • The population >65yrs old will double by 2040

  • Americans with AFib projected to increase to 16M by 2050 (100M worldwide)

Unfortunately, current AFib treatments have suboptimal efficacy.

• Drugs to control heart rhythm have <50% efficacy and can cause life threatening arrhythmias and significant side effects.

• For drug refractory patients, cardiac ablation is moderately successful (70-80%) treating early stage (paroxysmal) AFib, however often requires repeat procedures and irreversibly destroys cardiac tissue.

• Most troubling is cardiac ablation’s 50-65% success treating more advanced stage (persistent) AFib representing the majority of symptomatic, drug refractory AF patients.

• Despite best efforts, improvements in ablation catheters and energy sources have not led to a significant increase in ablation success.

Clearly, better therapies are needed. AFib is a multi-factorial disease with several key underlying molecular mechanisms. Since cardiac ablation does not target these mechanisms, it fails to arrest the underlying disease process.

For more information on Atrial Fibrillation, please reference the American Heart Association https://www.heart.org/en/health-topics/atrial-fibrillation